Heidelberg Pharma Ag · XETR:HPHA

Heidelberg Pharma — Investor Presentation (January 2026)

19 slides from Heidelberg Pharma's investor presentation, January 2026

  1. Slide 1: Innovative ADCs With a New Payload: Amanitin

    INNOVATIVE ADCS WITH A NEW PAYLOAD: AMANITIN Corporate Presentation • January 2026

  2. Slide 2: Safe Harbor

    Safe Harbor FORWARD LOOKING STATEMENTS This communication contains certain forward-looking statements, product liability and limitations of insurance, limitations of supplies, relating to the Company’s business, which can be identified by the competition from other biopharmaceutical, chemical and us

  3. Slide 3: Proprietary Amanitin Payload Technology to Generate a Disruptive New Class of ADCs

    Heidelberg Pharma's Proprietary Amanitin Payload Technology to Generate a Disruptive New Class of ADCs Novel MoA Biomarker for Stratification Single Player Overcoming resistance of High-risk Patients M-Protein & IgG Change Over Standard Risk OS - 110 months 20 11 Cycles of HDP-101 Levels (g/dL) 15 C

  4. Slide 4: ATAC - Innovative ADCs With Amanitin Payload

    ATAC - Innovative ADCs With Amanitin Payload Payload: α-Amanitin HDP-101 – anti-BCMA • Identified in Amanita phalloides mushroom • Completely novel MOA: • Inhibition of RNA Polymerase II • Kills dormant/non-dividing tumor cells • Circumvents resistance via new mechanism • Synthetic amanitin derivati

  5. Slide 5: HDP-101 Phase I/IIa Trial Design in Relapsed/Refractory Multiple Myeloma

    HDP-101 Phase I/IIa Trial Design in Relapsed/Refractory Multiple Myeloma 218 µg/kg Split 1st dose & Ongoing C10 premed*, then Q3W Phase I: Dose Escalation Q3W intravenous dosing, BLRM Design 175 µg/kg Split 1st dose & C9 premed*, then Q3W Q1W split C8 dosing Arm B Objectives 140 µg/kg Split 1st dose

  6. Slide 6: HDP-101 – Phase I Efficacy Data Cohort 5-8

    HDP-101 – Phase I Efficacy Data Cohort 5-8 10101_P40 C (112.5 µg/kg) (140 µg/kg) 10101_P37 C * Cohort 8 10101_P42 B 10101_P41 C Progressive disease (PD) 10101_P39 C Stable disease (SD) 10101_P38 B Minimal response (MR) 10101_P36 B Partial response (PR) 10101_P35 C Very good partial response (VGPR) S

  7. Slide 7: HDP-101 – Phase I Preliminary Efficacy Data (Cohort 8)

    HDP-101 – Phase I Preliminary Efficacy Data (Cohort 8) Cohort 8 Progressive disease (PD) (140 µg/kg) Stable disease (SD) Minimal response (MR) Partial response (PR) Very good partial response (VGPR) Stringent complete response (CR) 10101_P40 C Ongoing treatment 10101_P37 C n.e. not evaluated * 10101

  8. Slide 8: M-protein % Change from Baseline

    M-protein % Change from Baseline 10101_P01 10101_P02 10101_P03 10101_P04 Cohort 1 Cohort 2 (20 µg/kg) (40 µg/kg) 10101_P05 Readout: 3 November 2025 10101_P06 10101_P07 Cohort 3 (60 µg/kg) 10101_P08 10101_P09 10101_P11 10101_P12 Cohort 4 (80 µg/kg) 10101_P10 10101_P28 A 10101_P26 B 10101_P21 C 10101_

  9. Slide 9: No Signs of Thrombocytopenia or Liver Damage

    No Signs of Thrombocytopenia or Liver Damage Cohort 8 (140 µg/kg) Platelets AST ALT 550 400 400 500 350 350 450 300 300 400 350 250 250 300 U/l U/l 200 G/l 200 250 200 150 150 150 Gr 1 100 100 100 Gr 2 50 50 50 Gr 3 Gr 4 0 0 0 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 1 8 15 22 29 36 43 50 57 64 71

  10. Slide 10: Most Common Treatment-Emergent AEs - Cohort 8 only

    Most Common Treatment-Emergent AEs - Cohort 8 only Cohort 8 (N=8) Cohort 8 (N=8) Preferred Term Any CTCAE Grade 3-4 Thrombocytopenia 2 0 FAVORABLE SAFETY OF HDP-101 Anaemia 2 0 Arthralgia 0 0 • Overall mild AEs: no signs of ocular or renal tox, Fatigue 1 0 myelosuppression or liver damage Aspartate

  11. Slide 11: Objective Response Rates (ORR)

    Objective Response Rates (ORR) 70% PRELIMINARY EFFICACY 60% 57% • Multiple responses were seen (from 90 µg/kg) across 50% different dosing arms, confirming that changes in the dose distribution maintained the anti-tumor effect while 40% 38% 29% improving drug tolerability • We observed 38% ORR in Co

  12. Slide 12: High Tolerability and Good Efficacy at Doses below MTD

    High Tolerability and Good Efficacy at Doses below MTD A Comparative Analysis with Multiple Myeloma Approved Therapies HDP-101 Blenrep Tecvayli Carvykti ORR 57% - n=7 30-35% - n=194 63% - n=165 90% - n=39 Dose 0.140 mg/kg Q3W 2.5/3.4 mg/kg Q3W 1.5 mg/kg QW (opt. Q2W) 2.5/3.4 mg/kg TEAEs Cohort 8 – P

  13. Slide 13: Amanitin-ADC Shows Deep Responses Below MTD

    Amanitin-ADC Shows Deep Responses Below MTD • Phase I dose escalation data demonstrates therapeutic window in patients • HDP-101 data provide clinical validation for the Amanitin platform • Promising safety profile: no ocular tox, no renal tox, no myelosuppression, no liver damage • Overcome resista

  14. Slide 14: HDP-101 Relevant Throughout the Spectrum of Treatment in Early Relapse

    HDP-101 Relevant Throughout the Spectrum of Treatment in Early Relapse with Combination Regimens Potential Study Populations HDP-101 Regimens Near Term Priority Establish Post-BCMA Monotherapy Monotherapy in Late-line Setting Len-exposed (similar to DREAMM-8) Combination (IMiD + dex) Compete with Bl

  15. Slide 15: Planned Studies Tap into Large, Growing Patient Populations

    Planned Studies Tap into Large, Growing Patient Populations, with High Unmet Need to Prolong Survival Treatment Total Addressab. Range of Annual Peak 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Duration Population Size Analog Shares Addressab. (U.S.) (%, WW) US Market1 Accelerated approval Ful

  16. Slide 16: Finances – as of Aug 31, 2025

    Finances – as of Aug 31, 2025 Total Assets (including cash) EUR 54.1m Equity EUR 10.5m Common shares 46.8m Major Shareholders dievini & affiliated parties 44%, Huadong Medicine 35% Cash as of August 31, 2025 - Expected to Fund Operations until Q2 2026 © Heidelberg Pharma AG 16

  17. Slide 17: Partial Monetization of Royalty Stream for TLX250-CDx

    Partial Monetization of Royalty Stream for TLX250-CDx Partial monetization of royalty stream for TLX250-CDx in the field of diagnostic use Key terms of the agreement between Heidelberg Pharma and HealthCare Royalty: • $25 m upfront payment at closing (March 2024), no repayment obligation in case of

  18. Slide 18: ADC Program Pipeline: Multiple Potential Value Drivers

    ADC Program Pipeline: Multiple Potential Value Drivers Product Target Indication Research Preclinic Phase I Phase II Phase III Approval Partner HDP-101 BCMA Multiple Myeloma ------------------------------------------------------------------------------------------ Huadong (China+) Potential for auto

  19. Slide 19: Innovative ADCs With a New Payload: Amanitin

    INNOVATIVE ADCS WITH A NEW PAYLOAD: AMANITIN Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 10090 investors@hdpharma.com Corporate Presentation www.heidelberg-pharma.com

Heidelberg Pharma — Investor Presentation (January 2026) on 6ix